Monoclonal antibodies targeting either PD-1 (nivolumab, pembrolizumab) or PD-L1 (atezolizumab, avelumab, durvalumab) effectively remove these brakes on the immune system to promote an effective immune response in cancer [81]. This evidence concerns the gene PDCD1 and cancer.